Comparison of Adverse Drug Reactions with Donepezil versus Memantine: Analysis of the French Pharmacovigilance Database

被引:10
|
作者
Babai, Samy [1 ]
Auriche, Pascal [2 ]
Le-Louet, Herve [1 ]
机构
[1] Hop Henri Mondor, Ctr Reg Pharmacovigilance, F-94010 Creteil, France
[2] Afssaps, St Denis, France
来源
THERAPIE | 2010年 / 65卷 / 03期
关键词
pharmacovigilance; adverse drug reactions; memantine; donepezil; Alzheimer disease; SEVERE ALZHEIMERS-DISEASE; CHOLINESTERASE-INHIBITORS; DEMENTIA; MODERATE; PREVALENCE; MANAGEMENT;
D O I
10.2515/therapie/2010008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. Since donepezil and memantine are currently used for treating Alzheimer's disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use. Methods. All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 years were retrospectively analysed. Results. The most frequent adverse drug reactions with donepezil alone and memantine alone were respectively: bradycardia (10% versus 7%), weakness (5% versus 6%) and convulsions (4% versus 3%). Conclusion. The most adverse drug events with donepezil and with memantine are associated with elderly people, even if they do not receive any other treatment. Donepezil and memantine have an acceptable safety profile but physicians should take special care when they prescribe any drug known to cause bradycardia or to reduce the epileptogenic threshold.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 50 条
  • [21] Infectious Adverse Drug Reactions of Idelalisib: study in the French Pharmacovigilance Database
    Torres, A. M. Montoya
    Pinel, S.
    Yelehe-Okouma, M.
    Eftekhari, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 64 - 64
  • [22] Adverse Drug Reactions to Gabapentin and PregabalinA Review of the French Pharmacovigilance Database
    Régis Fuzier
    Isabelle Serres
    Emmanuelle Guitton
    Maryse Lapeyre-Mestre
    Jean-Louis Montastruc
    Drug Safety, 2013, 36 : 55 - 62
  • [23] Adverse drug reactions to dopaminergic agonists: a study in the French pharmacovigilance database
    Bondon-Guitton, E.
    Perez-Lloret, S.
    Rascol, O.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 82 - 82
  • [24] Adverse drug reactions in adolescents: a comparative study in the French pharmacovigilance database
    Portolan, G.
    Michot, J.
    Rousseau, V.
    Pageot, C.
    Damase-Michel, C.
    Montastruc, J. L.
    Lacroix, I.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 56 - 56
  • [25] Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database
    Durrieu, G.
    Olivier, P.
    Bagheri, H.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (05) : 555 - 558
  • [26] Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis of the French Pharmacovigilance database
    Teisseyre, A.
    Olivier, P.
    Montastruc, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 25 - 25
  • [27] Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
    Olivier-Abbal, Pascale
    Teisseyre, Anne-Charlotte
    Montastruc, Jean-Louis
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [28] Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
    Pascale Olivier-Abbal
    Anne-Charlotte Teisseyre
    Jean-Louis Montastruc
    Medical Oncology, 2013, 30
  • [29] Adverse drug reactions to apomorphine: A worldwide pharmacovigilance database analysis
    Auffret, M.
    Le Corre, C.
    Scailteux, L. M.
    Verin, M.
    Polard, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 97 - 97
  • [30] Adverse drug reactions from adrenaline auto-injectors: Analysis of the French pharmacovigilance database
    Pouessel, Guillaume
    Petitpain, Nadine
    Tanno, Luciana Kase
    Gautier, Sophie
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (09): : 955 - 958